A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled
clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with
Major Depressive Disorder.